EOSS takes off with biotechnology carve-out

150 150 EOSS Industries Holding GmbH

genspeed_team

Genspeed Biotech is the latest addition to the EOSS Group. The highly innovative Upper Austrian start-up has a diagnostic technology acquired from medical technology group Greiner Bio-One, which is fully in line with the global trend towards rapid disease detection.

EOSS founded the company at the end of 2016 together with former Greiner Bio-One managers Dr. Max Sonnleitner and Dr. Sonja Kierstein, and in the process acquired patents and assets from the Upper Austrian medical technology group. With now ten employees, the start-up continues to develop the patented technology, which is a highly scalable platform for rapid tests on DNA, RNA and protein basis. To date, rapid tests for multi-resistant hospital germs and periodontitis have been implemented on the platform, which are produced and distributed by the team. The technology is based on microfluidic biochips, miniaturized optical detection and automation and enables in vitro certified rapid tests for qualitative and quantitative analysis of DNA, RNA and proteins. Eliminating long hands-on times massively shortens the time to treatment initiation and prevents the administration of incorrect drugs.

Datenschutzeinstellungen
Wenn Sie unsere Website besuchen, kann sie Informationen über Ihren Browser aus bestimmten Diensten speichern, in der Regel in Form von Cookies. Hier können Sie Ihre Datenschutzeinstellungen ändern. Es ist zu beachten, dass das Blockieren einiger Arten von Cookies Ihre Erfahrungen auf unserer Website und die von uns angebotenen Dienste beeinträchtigen kann.
Click to enable/disable Google Analytics tracking code.
Click to enable/disable Google Fonts.
Click to enable/disable Google Maps.
Click to enable/disable video embeds.
Unsere Website verwendet Cookies, hauptsächlich von Drittanbietern. Definieren Sie Ihre Datenschutzeinstellungen und/oder stimmen Sie der Verwendung von Cookies zu. Besuchen Sie unsere Datenschutz Seite für weitere Informationen.